Last year, new drugs developed by domestic pharmaceutical companies recorded remarkable achievements overseas.

Hanmi Pharmaceutical's Rolontis (U.S. brand name Rolvedon) has continued to grow in the U.S. market. Rolontis is a neutropenia treatment developed by Hanmi Pharmaceutical and became the 33rd new domestic drug to be approved in Korea in March 2021. The drug was also approved in the U.S. in September of the same year.

Since its launch in the U.S. in the fourth quarter of 2022, Rolontis has posted cumulative sales of USD 110.3 million (approximately KRW 155 billion).

SK Biopharm's epilepsy drug Xcopri has also shown success in the U.S. market. Officially launched in